Please login to the form below

amyloidosis

This page shows the latest amyloidosis news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy, an underdiagnosed and potentially fatal form of ATTR amyloidosis. ... Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which

Latest news

Alnylam scores EU approval for RNAi drug Givlaari

Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

cardiomyopathy resulting from rare disease transthyretin-mediated amyloidosis (ATTR).
Vyndaqel a bright spot as Pfizer comes under pressure

The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier
NICE rejects Akcea’s rare inherited disorder drug Waylivra

Waylivra was Akcea’s second drug to reach the market last year after transthyretin-related amyloidosis (ATTR) therapy Tegsedi (inotersen).
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari

More from news
Approximately 3 fully matching, plus 37 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... pipeline. The company submitted its lumasiran
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

The drug is licensed to treat to adults with stage 1 or 2 polyneuropathy, the destruction of nerves that results from hereditary transthyretin- mediated (hATTR) amyloidosis, a rare, rapidly progressive, fatal ... The company is working with patient
Tough times for pharma in Portugal

spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis). ... The drug is to be granted marketing approval by the European Medicines Agency for the treatment of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

What does the future hold for Light-chain Amyloidosis?

What is Light-chain (AL) Amyloidosis? Amyloidosis is a group of rare, serious conditions caused by the abnormal folding of amyloid proteins that build up in tissue throughout the body. ... enhance recognition of AL Amyloidosis itself and the therapies
ASCO 2015: What you missed in Chicago

Three monoclonal antibodies were presented on the last day of ASCO - two in multiple myeloma and one in amyloidosis.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Vaccines writer – career opportunity to move into medcomms from ...: Highly competitive salary

Senior Account Exec > CSD – Medical Communications – UK, Lond...: Highly Competitive Salary, Bonus &Benefits

Scientific Director, MRNA/ Covid 19, Medical Communications, UK: Six figure salary

PR/ PA Account Executive (UK Healthcare Industry specialist, cam...: Competitive

Medical Writers > Scientific Directors – Medical Communicatio...: Highly Competitive Salary, Bonus &Benefits

Account Supervisor – Leading Healthcare Advertising Agency – New...: Highly Competitive Salary, Bonus &Benefits

B2B media account director: Competitive salary

Client Services Director, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

HR Manager – Recruitment/ Generalist combined role, Marketing ag...: circa £50K

Principal Medical Writer, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

Senior Medical Writer – Creative Healthcare Advertising – New Yo...: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?: Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:: Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs): How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...

Email:
Password:

Please login to the form below

amyloidosis

COVID-19 Updates and Daily News

Featured jobs

Quick links